• 1
    Olanow WC, Kieburtz K, Rascol O, et al; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-1071.
  • 2
    Birkmayer W, Hornykiewicz O. The effect of L-3,4-dihydroxyphenylalanine (L-DOPA) on akinesia in Parkinsonism. Wiener Klin Wochenschr 1961;73:787-788.
  • 3
    Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
  • 4
    Yahr MD. Clinical aspects of abnormal movements induced by L-dopa. In: Barbeau A, McDowell FH, editors. L-Dopa and Parkinsonism. Philadelphia, PA: F.A. Davis Company; 1970:101-108.
  • 5
    Rajput AH, Stern W, Laverty WH. Chronic low dose therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
  • 6
    Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson's disease subtypes: a 39-year clinicopathological study. Neurology 2009;73:206-212.